EPIRUS Biopharma (EPRS) Tops Q1 EPS by 4c

EPIRUS Biopharma (NASDAQ: EPRS) reported Q1 EPS of ($0.39), $0.04 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $25 thousand versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Xilio Therapeutics, Inc. (XLO) Tops Q2 EPS by 25c
• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance